Temporal evolution of human autoantibody response to cytoplasmic rods and rings structure during anti-HCV therapy with ribavirin and interferon-α

Immunologic Research

Volumn 60, Issue 1, 2014, Pages 38-49

  Keppeke, Gerson Dierley ^a,b   Satoh, Minoru ^c,d   Ferraz, Maria Lucia Gomes ^a   Chan, Edward K L ^b   Andrade, Luís Eduardo C ^a,e  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e Fleury   (Brazil)

Author keywords

Autoantibodies; Hepatitis C; IMPDH2; Interferon ; Ribavirin

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; AUTOANTIBODY; IMMUNOGLOBULIN G; IMPDH2 PROTEIN, HUMAN; INOSINATE DEHYDROGENASE; RIBAVIRIN;

CELL ORGANELLE; HEPATITIS C; HUMAN; IMMUNOLOGY;

ANTIVIRAL AGENTS; AUTOANTIBODIES; HEPATITIS C; HUMANS; IMMUNOGLOBULIN G; IMP DEHYDROGENASE; INTERFERON-ALPHA; ORGANELLES; RIBAVIRIN;

EID: 84930695328     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-014-8515-2     Document Type: Article

References (54)

1. Elkon K, Casali P. Nature and functions of autoantibodies. Nat Clin Pract Rheumatol. 2008;4(9):491–8.
2. Selmi C. Autoimmunity in 2011. Clin Rev Allergy Immunol. 2012;43(1–2):194–206.
3. Costenbader KH, Gay S, Alarcon-Riquelme ME, Iaccarino L, Doria A. Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? Autoimmun Rev. 2012;11(8):604–9.
4. Kofler R, Dixon FJ, Theofilopoulos AN. Genetic basis for autoantibody-production in murine models of systemic autoimmunity. Contrib Microbiol Immunol. 1989;11:206–30.
5. Kono DH, Theofilopoulos AN. Genetics of systemic autoimmunity in mouse models of lupus. Int Rev Immunol. 2000;19(4–5):367–87.
6. Seery JP, Carroll JM, Cattell V, Watt FM. Antinuclear autoantibodies and lupus nephritis in transgenic mice expressing interferon gamma in the epidermis. J Exp Med. 1997;186(9):1451–9.
7. Yoshida H, Satoh M, Behney KM, Lee CG, Richards HB, Shaheen VM, et al. Effect of an exogenous trigger on the pathogenesis of lupus in (NZB × NZW)F1 mice. Arthritis Rheum. 2002;46(8):2235–44.
8. Gelpi C, Rodriguez-Sanchez JL, Martinez MA, Craft J, Hardin JA. Murine graft vs host disease. A model for study of mechanisms that generate autoantibodies to ribonucleoproteins. J Immunol. 1988;140(12):4160–6.
9. Pollard KM. Perspectives. Autoantibodies and autoimmunity. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2005.
10. Peitsch MC, Tschopp J. Assembly of macromolecular pores by immune defense systems. Curr Opin Cell Biol. 1991;3(4):710–6.
11. Cohen S. Antibodies. Mod Trends Immunol. 1963;55:25–52.
12. Beveridge WI. Acquired immunity: viral infections. Mod Trends Immunol. 1963;102:130–44.
13. Saegusa J, Kiuchi Y, Itoh T. Antinucleolar autoantibody induced in mice by mercuric chloride—strain difference in susceptibility. Jikken Dobutsu. 1990;39(4):597–9.
14. Druet P, Ayed K, Bariety J, Bernaudin JF, Druet E, Girard JF, et al. Experimental immune glomerulonephritis induced in the rat by mercuric chloride. Adv Nephrol Necker Hosp. 1979;8:321–42.
15. Pusey CD, Bowman C, Morgan A, Weetman AP, Hartley B, Lockwood CM. Kinetics and pathogenicity of autoantibodies induced by mercuric chloride in the brown Norway rat. Clin Exp Immunol. 1990;81(1):76–82.
16. Saegusa J, Yamamoto S, Iwai H, Ueda K. Antinucleolar autoantibody induced in mice by mercuric chloride. Ind Health. 1990;28(1):21–30.
17. Ochel M, Vohr HW, Pfeiffer C, Gleichmann E. IL-4 is required for the IgE and IgG1 increase and IgG1 autoantibody formation in mice treated with mercuric chloride. J Immunol. 1991;146(9):3006–11.
18. Keppeke GD, Nunes E, Ferraz ML, Silva EA, Granato C, Chan EK, et al. Longitudinal study of a human drug-induced model of autoantibody to cytoplasmic rods/rings following HCV therapy with ribavirin and interferon-alpha. PLoS One. 2012;7(9):e45392.
19. Carcamo WC, Satoh M, Kasahara H, Terada N, Hamazaki T, Chan JY, et al. Induction of cytoplasmic rods and rings structures by inhibition of the CTP and GTP synthetic pathway in mammalian cells. PLoS One. 2011;6(12):e29690.
20. Carcamo WC, Ceribelli A, Calise SJ, Krueger C, Liu C, Daves M, et al. Differential reactivity to IMPDH2 by anti-rods/rings autoantibodies and unresponsiveness to pegylated interferon-alpha/ribavirin therapy in US and Italian HCV patients. J Clin Immunol. 2012;33(2):420–6.
21. Seelig HP, Appelhans H, Bauer O, Bluthner M, Hartung K, Schranz P, et al. Autoantibodies against inosine-5′-monophosphate dehydrogenase 2—characteristics and prevalence in patients with HCV-infection. Clin Lab. 2011;57(9–10):753–65.
22. Probst C, Radzimski C, Blocker IM, Teegen B, Bogdanos DP, Stocker W, et al. Development of a recombinant cell-based indirect immunofluorescence assay (RC-IFA) for the determination of autoantibodies against “rings and rods”-associated inosine-5′-monophosphate dehydrogenase 2 in viral hepatitis C. Clin Chim Acta. 2013;418:91–6.
23. Bairagya HR, Mukhopadhyay BP, Bera AK. Role of salt bridge dynamics in inter domain recognition of human IMPDH isoforms: an insight to inhibitor topology for isoform-II. J Biomol Struct Dyn. 2011;29(3):441–62.
24. Natsumeda Y, Ohno S, Kawasaki H, Konno Y, Weber G, Suzuki K. Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem. 1990;265(9):5292–5.
25. Covini G, Carcamo WC, Bredi E, von Muhlen CA, Colombo M, Chan EK. Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Antivir Ther. 2011;17(5):805–11.
26. Thomas EC, Gunter JH, Webster JA, Schieber NL, Oorschot V, Parton RG, et al. Different characteristics and nucleotide binding properties of inosine monophosphate dehydrogenase (IMPDH) isoforms. PLoS One. 2012;7(12):e51096.
27. Wettey FR, Jackson AP. Indirect immunofluorescence microscopy. Subcell Biochem. 2006;40:427–9.
28. Satoh M, Langdon JJ, Hamilton KJ, Richards HB, Panka D, Eisenberg RA, et al. Distinctive immune response patterns of human and murine autoimmune sera to U1 small nuclear ribonucleoprotein C protein. J Clin Invest. 1996;97(11):2619–26.
29. Satoh M, Treadwell EL, Reeves WH. Pristane induces high titers of anti-Su and anti-nRNP/Sm autoantibodies in BALB/c mice. Quantitation by antigen capture ELISAs based on monospecific human autoimmune sera. J Immunol Methods. 1995;182(1):51–62.
30. Satoh M, Langdon JJ, Reeves WH. Clinical applications of an anti-ku antigen-capture ELISA. Clin Immunol Newsl. 1993;13(2–3):23–31.
31. Trieu EP, Targoff IN. SDS-PAGE for (3)(5)S immunoprecipitation and immunoprecipitation western blotting. Methods Mol Biol. 2012;869:215–33.
32. Dotzauer G. Effects of environment on an antigen–antibody reaction; reactions dependent on the electrolyte concentration and Hofmeister series. Dtsch Z Gesamte Gerichtl Med. 1958;47(4):573–9.
33. Weinbach R. Mechanism of antigen–antibody reactions. Nature. 1964;202:409–10.
34. Schmitz H, Haas R. Determination of different cytomegalovirus immunoglobulins (IgG, IgA, IgM) by immunofluorescence. Arch Gesamte Virusforsch. 1972;37(1):131–40.
35. Hayward AR. Development of the immune response. Clin Allergy. 1973;3(Suppl):559–70.
36. Averbeck M, Gebhardt C, Emmrich F, Treudler R, Simon JC. Immunologic principles of allergic disease. J Dtsch Dermatol Ges. 2007;5(11):1015–28.
37. Enders G, Knotek F. Rubella IgG total antibody avidity and IgG subclass-specific antibody avidity assay and their role in the differentiation between primary rubella and rubella reinfection. Infection. 1989;17(4):218–26.
38. Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S41–52.
39. Goodnow CC, Vinuesa CG, Randall KL, Mackay F, Brink R. Control systems and decision making for antibody production. Nat Immunol. 2010;11(8):681–8.
40. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, et al. Dengue: a continuing global threat. Nat Rev Microbiol. 2010;8(12 Suppl):S7–16.
41. Chanama S, Anantapreecha S, A-nuegoonpipat A, Sa-gnasang A, Kurane I, Sawanpanyalert P. Analysis of specific IgM responses in secondary dengue virus infections: levels and positive rates in comparison with primary infections. J Clin Virol. 2004;31(3):185–9.
42. Iwakata S, Rhodes AJ, Labzoffsky NA. The significance of specific IgM antibody in the diagnosis of rubella employing the immunofluorescence technique. Can Med Assoc J. 1972;106(4):327–30.
43. Frisch-Niggemeyer W. Rapid separation of immunoglobulin M from immunoglobulin G antibodies for reliable diagnosis of recent rubella infections. J Clin Microbiol. 1975;2(5):377–81.
44. Vaz CA, Mackenzie DW, Hearn VM, Camargo ZP, Singer-Vermes LM, Burger E, et al. Specific recognition pattern of IgM and IgG antibodies produced in the course of experimental paracoccidioidomycosis. Clin Exp Immunol. 1992;88(1):119–23.
45. Arvin AM, Koropchak CM. Immunoglobulins M and G to varicella-zoster virus measured by solid-phase radioimmunoassay: antibody responses to varicella and herpes zoster infections. J Clin Microbiol. 1980;12(3):367–74.
46. Schaade L, Kleines M, Hausler M. Application of virus-specific immunoglobulin M (IgM), IgG, and IgA antibody detection with a polyantigenic enzyme-linked immunosorbent assay for diagnosis of Epstein–Barr virus infections in childhood. J Clin Microbiol. 2001;39(11):3902–5.
47. Bjorkman C, Naslund K, Stenlund S, Maley SW, Buxton D, Uggla A. An IgG avidity ELISA to discriminate between recent and chronic Neospora caninum infection. J Vet Diagn Invest. 1999;11(1):41–4.
48. Aguado-Martinez A, Alvarez-Garcia G, Arnaiz-Seco I, Innes E, Ortega-Mora LM. Use of avidity enzyme-linked immunosorbent assay and avidity Western blot to discriminate between acute and chronic Neospora caninum infection in cattle. J Vet Diagn Invest. 2005;17(5):442–50.
49. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature. 2005;436(7053):946–52.
50. Strasak AM, Kim AY, Lauer GM, de Sousa PS, Ginuino CF, Fernandes CA, et al. Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil. BMC Infect Dis. 2011;11:15.
51. Vergani D, Mieli-Vergani G. Autoimmune manifestations in viral hepatitis. Semin Immunopathol. 2013;35(1):73–85.
52. Ferri S, Muratori L, Lenzi M, Granito A, Bianchi FB, Vergani D. HCV and autoimmunity. Curr Pharm Des. 2008;14(17):1678–85.
53. Toubi E, Gordon S, Kessel A, Rosner I, Rozenbaum M, Shoenfeld Y, et al. Elevated serum B-lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun. 2006;27(2):134–9.
54. Landau DA, Rosenzwajg M, Saadoun D, Klatzmann D, Cacoub P. The B lymphocyte stimulator receptor–ligand system in hepatitis C virus-induced B cell clonal disorders. Ann Rheum Dis. 2009;68(3):337–44.